Join us for a virtual fireside chat with visionaries in biopharma! We’re bringing together biopharma key option leaders recognized for their contributions to innovative human disease research and translational safety to share their thoughts on technologies that are transforming drug discovery.
New Frontiers in 3D | Visionaries Speak
Claim This Podcastby InSphero
4 episodes
Updated Daily
Accepts GuestsHas Sponsors
Podcast Overview
Join us for a virtual fireside chat with visionaries in biopharma! We’re bringing together biopharma key option leaders recognized for their contributions to innovative human disease research and translational safety to share their thoughts on technologies that are transforming drug discovery.
Language
🇺🇲
Publishing Since
2/10/2021
1 verified contact email on file for New Frontiers in 3D | Visionaries Speak
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
October 4, 2021
Is Drug Screening in 3D Ready for Automation?
3D cell-based assays, including organoids, spheroids, and advanced organ-on-chip systems, have grown in popularity in the scientific community. Compared to conventional 2D assays, 3D assays deliver more biological relevance, more closely mimic the tissue microenvironment, and offer extended culturing necessary to assess physiological drug effects. Still, their use in larger-scale drug screening programs is limited, despite these clear advantages. In this discussion, Dr. Terry Riss from Promega, Dr. Tim Spicer from Scripps Research, and Dr. Jan Lichtenberg from InSphero explored the latest state-of-the-art automated 3D cell-based assays and focused on progress and obstacles on the way to fully automated screening in 3D. During the event, our panelists address questions and topics, such as: - What are the advantages of moving to phenotypic screens in 3D? - How do you choose the right 3D modality (spheroid, organoid, other scaffold-based approaches) and supporting cells, for your research? - How do you select assays (biochemical vs. imaging vs. omics) from 3D models that automate well, and deliver consistent results? - Use cases for automated 3D cell-based assays in the drug R&D process, safety vs. discovery - What are the key hurdles, and how do we overcome them?
May 3, 2021
T1D: Emerging Perspectives on Disease Pathogenesis, Prevention and Treatment
Our understanding of the human T1D etiology along with proposed therapeutic options has greatly advanced during the last decades. Nevertheless, the rate of bench to bedside translation is still disappointingly slow. During the discussion, our panelists explored key topics on: Major discoveries and knowledge gaps in our understanding of T1D pathogenesis. Emerging therapies to treat or prevent T1D, and their potential challenges.
April 23, 2021
Does Physiological Complexity Kill Scalability?
During this roundtable about industrial applications for complex, yet scalable in vitro models for drug discovery, we discussed the importance of balancing experimental complexity and scalability, and how thoughtful engineering can ensure successful translation from academia to industry. Our panelists explored key topics, such as: Why are biological complexity and experimental scalability both essential for producing meaningful and robust datasets? What are the trade-offs between complexity and scalability? In which stages of research and development are scalability most critical? How does scalability of complex systems influence drug development? What are the next steps to ensure translatability of complex model systems?
4 total episodes available
Deep-dive analytics for New Frontiers in 3D | Visionaries Speak
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is New Frontiers in 3D | Visionaries Speak?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.